In this week's EuroBiotech Report, with AstraZeneca now back in play--if it chooses--talk of M&A involving European drugmakers has ratcheted up once again after a brief, post-Shire lull. And more.
Medtronic wants to be known for manufacturing high-quality devices and providing related services as well. To that end, the company today announced the acquisition of privately held Italian company NGC Medical S.p.A.
Swedish contract developer Recipharm is looking to expand its share of the European manufacturing market, trading $164.5 million for Italy's Corvette Pharmaceutical Services.
In this week's EuroBiotech Report, data on the antibiotic AstraZeneca is developing with Actavis' Forest Laboratories and some oncology compounds have burnished AstraZeneca's pipeline, a development that means the Anglo-Swedish drugmaker may now be too expensive to be attractive to Pfizer. And more.
In this week's EuroBiotech Report, a court convicted NeuroSearch of stock price manipulation and imposed a fine of DKK 5 million ($0.9 million) more than four years after NeuroSearch published the clinical trial results--and subsequent reappraisal--that caused its stock to surge and slump. And more.
Although the biggest med tech companies likely pay the bulk of the reported $1.4 billion in excise taxes levied on the industry during its first year in 2013, the tax adds to an already heavy burden for small and midsized companies.
In the 11 years since the Singapore government created a biologics CMO to kickstart the local sector, a who's who of biopharma manufacturers have opened plants in the country. Baxter is among the latest to set up shop in Singapore and is already pushing ahead with expansion plans.
In this week's EuroBiotech Report, Roche took another step back into RNA, striking a $450 million (€335 million) deal to acquire Santaris Pharma and committing to making the Danish biotech's lab its RNA therapeutics research unit. And more.
In this week's EuroBiotech Report, the last week of July was a massive one for European biotech IPOs, with BioBlast Pharma, Innocoll, Macrocure, Mapi Pharma and VBL Therapeutics all heading to the Nasdaq. All of the companies struggled though. And more.
Germany's Merck KGaA is expanding its headquarters and manufacturing operations in Darmstadt, Germany. On Monday, Merck said it is investing about €27 million (about $36.3 million) to build two power plants that it says will provide more power more efficiently, while reducing carbon dioxide emissions in the area.